Sihuan Pharmaceutical Completes Strategic Investment in Hanteng Biotechnology for Collagen-Based Medical Aesthetics
According to an announcement by Sihuan Pharmaceutical (00460), its subsidiary Meiyan Space Biotechnology has completed a strategic investment in Hanteng Biotechnology recently. The two parties plan joint commercialization of Hanteng's full-length recombinant human Type III collagen, with Meiyan Spac
SIHUAN PHARM-0.61%
GateNews·10-08 13:01
